<DOC>
	<DOCNO>NCT00005673</DOCNO>
	<brief_summary>This 2-part study test safety anti-HIV activity capravirine alone , safety , anti-HIV activity , drug interaction capravirine combine anti-HIV drug . Capravirine belong class drug call non-nucleoside reverse transcriptase inhibitor ( NNRTIs ) , effective use together drug , include nucleoside reverse transcriptase inhibitor ( NRTIs ) protease inhibitor . Normal volunteer 18 year age old may enroll Part 1 study . HIV-infected patient 18 year age old previously treat NNRTI ( efavirenz , nevirapine , delavirdine ) may participate Part 2 . All prospective study participant screen eligibility physical examination , blood test , urine test electrocardiogram ( ECG ) . Part 1 - Volunteers randomly assign one two treatment group follow : Group 1 receive capravirine alone 7 day capravirine plus efavirenz ( another NNRTI ) additional 10 day . On day 1 , participant physical examination , urine test laboratory blood test . Blood sample collect first dose capravirine give 0.5 , 1 , 2 , 4 , 6 , 8 12 hour dose . A small plastic tube place vein avoid multiple needle stick . On day 8 , participant another physical examination laboratory blood test . Blood sample draw describe . In even day 8 , efavirenz add regimen . On day 18 ( last day study ) , participants another physical examination blood test . Blood collect described . Group 2 take capravirine alone 8 ) day capravirine plus ritonavir ( protease inhibitor ) additional 8 day . Physical examination , urine test , blood collection do describe day 1 , day 8 day 16 ( last day ) study . Part 2 - Patients take capravirine alone 7 day . On day 1 , patient physical examination , urine test laboratory blood test . Blood sample collect first dose capravirine give 0.5 , 1 , 2 , 4 , 6 , 8 12 hour dose . A small plastic tube place vein avoid multiple needle stick . On day 8 , patient another physical examination laboratory blood test . Blood sample draw describe . Additional drug add regimen ( vary dos accord group ) , follow : Group 1 - efavirenz plus abacavir Group 2 - ritonavir plus efavirenz plus abacavir Group 3 - ritonavir plus efavirenz plus abacavir On day 15 , procedure perform day 8 repeat . Patients option blood draw daily day 2 7 measure HIV-1 viral load lumbar puncture ( spinal tap ) do day 2 7 measure well capravirine get central nervous system . After day 15 , patient group continue drug regimen week 48 determine treatment effective patient . Physical examination , viral load measurement , white blood cell count blood test do periodically throughout trial . Within 4 week end study , patient follow another physical examination , blood urine test , ECG .</brief_summary>
	<brief_title>Safety Anti-HIV Activity Capravirine Alone Combination With Other Anti-HIV Drugs</brief_title>
	<detailed_description>This open-label , phase I study examine safety anti-HIV activity investigational non-nucleoside reverse transcriptase inhibitor , capravirine . The primary objective study 1 ) To evaluate safety pharmacokinetics capravirine combine efavirenz ( low-dose ) ritonavir non-HIV-infected volunteer ; 2 ) To evaluate safety , virologic activity , pharmacokinetics capravirine combine efavirenz , ( low-dose ) ritonavir , abacavir HIV-infected patient ; 3 ) To evaluate safety , virologic activity , pharmacokinetics once-daily regimen capravirine , efavirenz , ( low-dose ) ritonavir , abacavir HIV-infected patient . The study conduct 2 part . Part I examine safety , pharmacokinetics , potential drug interaction capravirine antiretroviral agent non-HIV-infected volunteer . Sixteen volunteer ( 8 per group ) receive capravirine monotherapy ( 7 day ) , follow addition either : 1 ) efavirenz ( 10 day ) ; 2 ) ritonavir ( 8 day ) . Part II examine safety , virologic activity , pharmacokinetics , potential drug interaction capravirine HIV-infected patient . Thirty patient ( 10 per group ) receive capravirine monotherapy ( 7 day ) , follow randomize addition : 1 ) efavirenz/abacavir ( 7 day ) ; 2 ) ritonavir/efavirenz/abacavir ( 7 day ) twice-daily regimen ; 3 ) ritonavir/efavirenz/abacavir ( 7 day ) once-daily regimen . [ Doses capravirine may change depend upon pharmacokinetic data obtain Part I study . ] The primary efficacy endpoint time-to-virologic-failure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>CONTROL Documented HIV1 seronegative , confirm ELISA Western blot . Male female , least 18 year age . Laboratory value within establish National Institute Allergy Infectious Diseases ( NIAID ) guideline participation clinical study . Unremarkable physical exam Signed write informed consent . Must use ( , depend agent , must use last 28 day ) medication know inhibit induce cytochrome P450 initial period study period ( Arm 1 : Screening visit Day 17 ; Arm 2 : Screening visit Day 15 ) . After initial period , use agent permit casebycase basis per Investigator 's clinical judgement ; necessary , additional PK study may perform . The prohibited medication include , limited : isoniazid , rifampin , rifabutin , astemizole , terfenadine , cisapride , cimetidine , triazolam , midazolam , quinidine , nifedipine , diltiazem , verapamil , amiodarone , ergot alkaloid , carbamazepine , phenytoin hydantoin , phenobarbital barbiturate , propoxyphene , dexamethasone , oral contraceptive , antidepressant ( fluoxetine , paroxetine , imipramine , amitriptyline , nefazodone ) , azole antifungal ( ketoconazole , fluconazole , itraconazole ) macrolide antibiotic ( erythromycin , clarithromycin , dirithromycin ) , grapefruit juice . Must use highly plasma protein bound drug , include limited , warfarin phenytoin . Must receive treatment chronic Hepatitis B infection lamivudine ( 3TC ) . Must use antiretroviral therapy indicate study regimen . Must history significant allergy , hypersensitivity reaction , adverse reaction abacavir , efavirenz , ritonavir . Must able obtain venous access sample collection . Must psychological/sociological condition addictive disorder would preclude compliance protocol . Females must pregnant lactating . Must willing use adequate barrier contraception method ( oral contraceptive ) procreation potential exists . PATIENT Document HIV1 seropositive , confirm ELISA Western blot . CD4 great 300/mm ( 3 ) HIV1 RNA viral load great 5,000 copy per mL . Male female , least 18 year age . Adequate hematology ( absolute neutrophil count great equal 1500/mm ( 3 ) , platelet great equal 75,000/mm ( 3 ) , hemoglobin great equal 9 g/dL ) . Adequate renal function ( serum creatinine less equal 1.5 time upperlimitofnormal [ ULN ] ) . Adequate liver function ( aspartate aminotransferase [ AST/SGOT ] , alanine aminotransferase [ ALT/SGPT ] total bilirubin less equal 1.5 time ULN ) . Signed write informed consent . Must prior treatment nonnucleoside reverse transcriptase inhibitor . Must history significant allergy , hypersensitivity reaction , adverse reaction abacavir ritonavir . Must evidence clinical genotypic resistance abacavir . Must active uncontrolled infection . Must unstable severe concurrent medical condition . Must concomitant use antiretroviral therapy indicate study regimen . Must current treatment chronic Hepatitis B lamivudine ( 3TC ) . Must use ( , depend agent , must use last 28 day ) medication know inhibit induce cytochrome P450 initial period study period ( Screening visit Day 14 ) . After initial period , use agent permit casebycase basis per Investigator 's clinical judgement ; necessary , additional PK study may perform . The prohibited medication include , limited : isoniazid , rifampin , rifabutin , astemizole , terfenadine , cisapride , cimetidine , triazolam , midazolam , quinidine , nifedipine , diltiazem , verapamil , amiodarone , ergot alkaloid , carbamazepine , phenytoin hydantoin , phenobarbital barbiturate , propoxyphene , dexamethasone , oral contraceptive , antidepressant ( fluoxetine , paroxetine , imipramine , amitriptyline , nefazodone ) , azole antifungal ( ketoconazole , fluconazole , itraconazole ) macrolide antibiotic ( erythromycin , clarithromycin , dirithromycin ) , grapefruit juice . Must current use highly plasma bound drug , include limited , warfarin phenytoin . Must current use , use within last 28 day , investigational agent . Must cytotoxic chemotherapy , interferon treatment radiation therapy within last 28 day . Must psychological/sociological condition addictive disorder would preclude compliance protocol . Females must pregnant lactating . Must willing use adequate barrier contraception method ( oral contraceptive ) procreation potential exists . ( male female )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>NNRTI</keyword>
</DOC>